m+Medelevator.RU
← Поиск публикаций
EMBO molecular medicine · 2024

Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Gambelli Alice, Nespolo Anna, Rampioni Vinciguerra Gian Luca, Pivetta Eliana, Pellarin Ilenia, Nicoloso Milena S, Scapin Chiara, Stefenatti Linda, Segatto Ilenia, Favero Andrea, D'Andrea Sara, Mucignat Maria Teresa, Bartoletti Michele, Lucia Emilio, Schiappacassi Monica, Spessotto Paola, Canzonieri Vincenzo, Giorda Giorgio, Puglisi Fabio, Vecchione Andrea, Belletti Barbara, Sonego Maura, Baldassarre Gustavo

Аннотация

Platinum (PT)-resistant Epithelial Ovarian Cancer (EOC) grows as a metastatic disease, disseminating in the abdomen and pelvis. Very few options are available for PT-resistant EOC patients, and little is known about how the acquisition of PT-resistance mediates the increased spreading capabilities of EOC. Here, using isogenic PT-resistant cells, genetic and pharmacological approaches, and patient-derived models, we report that Integrin α6 (ITGA6) is overexpressed by PT-resistant cells and is necessary to sustain EOC metastatic ability and adhesion-dependent PT-resistance. Using in vitro approaches, we showed that PT induces a positive loop that, by stimulating ITGA6 transcription and secretion, contributes to the formation of a pre-metastatic niche enabling EOC cells to disseminate. At molecular level, ITGA6 engagement regulates the production and availability of insulin-like growth factors (IGFs), over-stimulating the IGF1R pathway and upregulating Snail expression. In vitro data were recapitulated using in vivo models in which the targeting of ITGA6 prevents PT-resistant EOC dissemination and improves PT-activity, supporting ITGA6 as a promising druggable target for EOC patients.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты